Immunomodulatory effects of tretinoin in combination with clindamycin. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Immunomodulatory effects of tretinoin in combination with clindamycin.

J Eur Acad Dermatol Venereol. 1998 Sep;11 Suppl 1:S2-7; discussion S28-9. Unique Identifier : AIDSLINE MED/99109051
Wauben-Penris PJ; Cerneus DP; van den Hoven WE; Leuven PJ; den Brok JH; Hall DW; Yamanouchi Europe B.V. Research Laboratories, Leiderdorp, The; Netherlands. wauben.nl@yamanouchi-eu.com

Abstract: BACKGROUND: Since acne is a multifactorial skin disease, therapies affecting several etiologic factors can have a higher than expected effectiveness. A combination of the antibiotic clindamycin phosphate and the retinoic acid tretinoin was developed. OBJECTIVE: Anti-inflammatory and immunomodulatory effects of tretinoin in vitro were studied on human keratinocytes and peripheral blood mononuclear cells (PBMCs). Effects of clindamycin phosphate on tretinoin effects were studied. METHODS: Anti-inflammatory effects on keratinocytes were assessed using an in vitro model with PMA (phorbol ester)-stimulated A431 cells (human epidermoid carcinoma). Immunomodulatory effects were measured on superantigen (SEB) stimulated PBMCs. RESULTS: Tretinoin showed very potent inhibition of PMA-stimulated IL-6 (interleukin 6) release by A431 cells. The addition of clindamycin phosphate did not interfere with this effect. Tretinoin very potently stimulated IL-5 release, and inhibited IFN gamma release by SEB-stimulated human PBMCs. This indicates an immunomodulatory effect, stimulating Th2, and inhibiting Th1 dominated responses. These features have been related to the healing of acne lesions. The addition of clindamycin phosphate did not interfere with the immunomodulatory effects of tretinoin. CONCLUSION: The combination of tretinoin and clindamycin phosphate can be expected to be very effective in acne therapy.
Keywords: JOURNAL ARTICLE Acne Vulgaris/DRUG THERAPY/IMMUNOLOGY Adjuvants, Immunologic/ADMINISTRATION & DOSAGE/*PHARMACOLOGY Anti-Inflammatory Agents/ADMINISTRATION & DOSAGE/*PHARMACOLOGY Antibiotics/ADMINISTRATION & DOSAGE/*PHARMACOLOGY Carcinogens/ADVERSE EFFECTS Carcinoma, Squamous Cell/IMMUNOLOGY/PATHOLOGY Clindamycin/ADMINISTRATION & DOSAGE/*PHARMACOLOGY Human Interferon Type II/ANTAGONISTS & INHIB Interleukin-5/SECRETION Interleukin-6/ANTAGONISTS & INHIB Keratinocytes/DRUG EFFECTS/IMMUNOLOGY Keratolytic Agents/ADMINISTRATION & DOSAGE/*PHARMACOLOGY Lymphocytes/DRUG EFFECTS/IMMUNOLOGY Monocytes/DRUG EFFECTS/IMMUNOLOGY Superantigens/PHARMACOLOGY Tetradecanoylphorbol Acetate/ADMINISTRATION & DOSAGE Th1 Cells/DRUG EFFECTS/IMMUNOLOGY Th2 Cells/DRUG EFFECTS/IMMUNOLOGY Tretinoin/ADMINISTRATION & DOSAGE/*PHARMACOLOGYKWDjournalarticleacnevulgaris/drugtherapy/immunologyadjuvants,immunologic/administration&dosage/KWDpharmacologyanti-inflammatoryagents/administration&dosage/KWDpharmacologyantibiotics/administration&dosage/KWDpharmacologycarcinogens/adverseeffectscarcinoma,squamouscell/immunology/pathologyclindamycin/administration&dosage/KWDpharmacologyhumaninterferontypeii/antagonists&inhibinterleukin-5/secretioninterleukin-6/antagonists&inhibkeratinocytes/drugeffects/immunologykeratolyticagents/administration&dosage/
990630
A9960953

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .